



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

July 12, 2016

Via E-mail

Dr. Shai Yarkoni
Chief Executive Officer
Collect Biomed Ltd.
23 Hata'as Street
Kfar Saba, Israel 44425

**Re: Collect Biomed Ltd.
Registration Statement on Form F-1
Filed July 7, 2016
File No. 333-212432**

Dear Dr. Yarkoni:

We have reviewed your registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments.

Business

Apotainer Selection Kit, page 63

1. Please revise your discussion of the BIRD Foundation grant to provide the following additional information:
 - Any known material provisions of the Cooperation and Project Funding Agreement;
 - The circumstances under which you may be required to repay the grant and how the amount subject to repayment is determined;
 - The milestones that result in an obligation to repay the grant; and

- Any circumstances which may result in your obligation to repay more than the amount of the initial grant.

Exhibit Index

2. Please file the amended agreements with Mr. Kasbian and Dr. Yarkoni as exhibits to the registration statement.

We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Act of 1933 and all applicable Securities Act rules require. Since the company and its management are in possession of all facts relating to a company's disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made.

Notwithstanding our comments, in the event you request acceleration of the effective date of the pending registration statement, please provide a written statement from the company acknowledging that:

- should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
- the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
- the company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Dr. Shai Yarkoni
Collect Biomed Ltd.
July 12, 2016
Page 3

Please refer to Rules 460 and 461 regarding requests for acceleration. We will consider a written request for acceleration of the effective date of the registration statement as confirmation of the fact that those requesting acceleration are aware of their respective responsibilities under the Securities Act of 1933 and the Securities Exchange Act of 1934 as they relate to the proposed public offering of the securities specified in the above registration statement. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.

Sincerely,

/s/ Suzanne Hayes

Suzanne Hayes
Assistant Director

cc: Oded Har-Even, Esq.
Zysman, Aharoni, Gayer and Sullivan & Worcester LLP